Xylo Bio Achieves Clinical-Stage Milestone with XYL-1001, a Highly Selective Neuroplastogen Targeting Major Depressive Disorder
BOSTON, Sept. 15, 2026 /PRNewswire/ -- Xylo Bio, a clinical-stage biotechnology company developing novel neurotherapeutics for psychiatric and neurological disorders, today announced the first participants dosed in its Phase 1 clinical study of XYL-1001, a novel, selective 5-HT2A agonist...
Covered in this story
What has happened since
- Xylem Inc. is down 3.1% since this was published, 35 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Xylem Inc.
- Baird: $122 → $165 by Jul 2027 · Outperform via MarketBeat
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $XYL yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Xylem Inc. →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.